First Blood-Based Diagnostic Test for Bipolar Disorder Also Differentiates Patients with Depression
|
By LabMedica International staff writers Posted on 10 Jun 2022 |

The number of people suffering from depression is estimated at 300 million worldwide, although up to 40% of them could actually have bipolar disorder that affects more than 60 million people worldwide. This chronic disorder is characterized by alternating depressive and manic phases. The depressive phases are similar to the so-called unipolar depression making the diagnosis complex and lengthy. As a result, diagnostic delays are significant, exceeding seven years on average. However, the management and treatments for bipolar disorder and depression differ significantly, making timely and reliable diagnosis paramount. Now, a new study has identified and validated a combination of blood biomarkers specific to bipolar disorder, leading to the development of the first diagnostic blood test for this disorder.
The study led by Alcediag (Montpellier, France) identified a panel of six blood biomarkers, major hallmarks of bipolar disorder. For the first time, a study, including a cohort of 410 subjects, has provided such a reliable, accurate test capable of differentiating the depressive phases of bipolar disorder from unipolar depression. The test, EDIT–B, with high diagnostic performance, specificity and sensitivity greater than 80%, was made possible thanks to the combined use of RNA editing and artificial intelligence (AI). The six biomarkers identified match modifications in the RNA sequence of genes associated with bipolar disorder.
The blood-based diagnostic test would provide biological, objective and rapidly available data to assist the physician in the process of diagnosing bipolar disorder. EDIT–B will enable them to optimize the therapeutic decision that today is plagued by the difficulty to establish a certain diagnosis. For patients, the benefits of the timely and accurate diagnosis and of the subsequent therapeutic strategy are many.
"The importance of our team's work is in harnessing the power of RNA editing, a mechanism which regulates RNA stability, splicing, gene expression and protein synthesis to create a high-performance test that is able to differentiate between unipolar depression and bipolar depression, thus paving the way to faster and more accurate diagnosis," said Dinah Weissmann, Alcediag's Deputy CEO.
Related Links:
Alcediag
Latest Molecular Diagnostics News
- Blood-Based RNA Biomarker Improves Prediction of Alzheimer’s Onset
- Gene Expression Test Supports Metastatic Risk Assessment in Melanoma
- Multiplex PCR Test Identifies Seven STI Pathogens in One Hour
- CSF Sequencing Test Aligns with Updated Brain Tumor Guidelines
- Framework Outlines Genomic Testing Strategy for Safer Drug Dosing in Africa
- Point-of-Care PCR Panel Delivers Vaginitis Results in 20 Minutes
- Blood Test Reveals Hidden Pancreatic Cancer After Treatment
- Gene Expression Test Refines Melanoma Biopsy Decision-Making
- Genomic Assays Predict Anthracycline Benefit in Early-Stage Breast Cancer
- Ultrasensitive ctDNA Assay Detects MRD in Breast, Colorectal, Renal Cancers
- Model Predicts Increased ALS Clinic Visits with Expanded Genetic Testing
- Genetic Marker Supports Anti-TNF Therapy Selection in Crohn’s Disease
- Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease
- Genomic Test Guides Taxane-Based Chemotherapy Selection in Breast Cancer
- RNA Blood Test May Enable Earlier Alzheimer’s Disease Diagnosis
- AI Reasoning Model Generates Diagnostic Leads for Unresolved Rare Disease Cases
Channels
Clinical Chemistry
view channel
FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
Chronic liver disease contributes substantially to mortality, and clinicians routinely screen adults with compensated cirrhosis for varices to prevent bleeding. However, endoscopy is invasive and reso... Read more
Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
Confirming pediatric inflammatory bowel disease (IBD) often requires imaging, endoscopy, and histopathology, prolonging time to diagnosis. Reliable, noninvasive blood tests remain an unmet need in routine... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention
Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Machine Learning Reveals Consistent Gut Microbiome Patterns in Colorectal Cancer
Colorectal cancer has been repeatedly linked to alterations in the gut microbiome, yet findings have often varied across small, heterogeneous studies. Reproducibility has been limited by differing sequencing... Read morePathology
view channel
AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
Immunotherapy has transformed care for select malignancies, yet predicting which patients with rare cancers are most likely to benefit remains challenging. Clinicians often have only limited biomarkers... Read more
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR
Countable Labs (Palo Alto, CA, USA) and Promega (Madison, WI, USA) have entered a co-marketing agreement that integrates the Promega Maxwell System for nucleic acid extraction with Countable Labs’ Countable... Read more




.jpg)



